L'Oréal Shares Drop 1.53% at Midday Following Galderma Announcement
L'Oréal shares are down this Friday, December 19, at midday, falling 1.30% to 371 euros from a previous close of 375.90 euros. Trading remains modest with only 0.03% of the capital having changed hands since the opening. This correction follows a slightly negative weekly trend of 0.48%, and extends the consolidation observed over three months with a decline of 2.13%. On an annual horizon, the French cosmetics giant still shows a positive performance of 8.23%, demonstrating relative resilience in a contrasting market environment. The price is now above its 50-day moving average set at 368.75 euros, but remains slightly below its 200-day average established at 372.34 euros, indicating a stabilization phase after recent movements.
Recent news from the group is still dominated by the December 8 announcement of the acquisition of an additional 10% in Galderma, bringing L'Oréal's total stake to 20% of the capital of the Swiss dermatology specialist. This transaction, whose amount was not disclosed, is expected to be finalized in the first quarter of 2026 after usual regulatory approvals. Nicolas Hieronimus, CEO of L'Oréal, emphasized that aesthetics is a key extension of the group's beauty business. A few days later, on December 12, L'Oréal received for the tenth consecutive year the triple AAA rating from the CDP organization, an unprecedented environmental distinction that makes the group the first and only company in the world to achieve this decennial recognition for its performance in climate, forests, and water security. These announcements follow the historic acquisition of Kering Beauté for 4 billion euros announced in October.
From a technical analysis perspective, the stock presents a neutral profile with an RSI at 50, signaling a balance between buyers and sellers without any overbought or oversold signals. The MACD configuration remains constructive with a MACD line at 3.14 points surpassing the signal line at 2.79 points, generating a positive histogram of 0.35 point which suggests the maintenance of a short-term bullish momentum despite the day's decline. The price is situated between a support threshold identified at 350.65 euros and a resistance at 377.95 euros, leaving limited room for short-term progression. The moderate monthly volatility of 4.73% and a nearly zero beta at -0.03 confirm a relatively uncorrelated evolution from the movements of the CAC 40. Investors will await the 2025 annual results scheduled for February 12, 2026, to assess the group's prospects after a year marked by an ambitious acquisition strategy and a repositioning towards high-growth segments of dermatology and medical aesthetics.
